CD123嵌合抗原受体治疗急性髓系白血病

T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.

PURPOSE OF REVIEW:
The purpose of this article is to discuss the rationale of targeting CD123 using chimeric antigen receptor (CAR) T cells for the treatment of leukemia.
RECENT FINDINGS:
CD123 is a leukemia-associated antigen that expresses at high levels in leukemic stem cells and leukemic blasts and low level in normal hematopoietic stem/progenitor cells. Immune-based therapies targeting CD123 are being developed. Preclinical data suggest that CD123 CAR T cells exhibit potent antileukemic activity and various impacts on normal hematopoiesis.
SUMMARY:
CD123 is an attractive surface target for novel antileukemic therapies. CD123 CAR T-cell-based immunotherapy is a promising treatment for patients with relapsed or refractory acute myeloid leukemia.


CD123嵌合抗原受体治疗急性髓系白血病
综述的目的：
这篇文章的目的是讨论靶向CD123的嵌合抗原受体修饰的T细胞治疗白血病的依据。
最新的发现：
CD123是白血病相关抗原，在白血病干细胞和白血病细胞表面高度表达，在正常造血干/祖细胞中低表达。以CD123为靶点的免疫治疗已经处于发展之中。临床数据显示CD123 CAR-T细胞具有抑制白血病的活性，并且对正常干细胞也有不少作用。
总结：
CD123 是一个新型的治疗白血病的很有吸引力的靶点，CD123 CAR-T细胞免疫治疗是一种很有前途的治疗复发性或难治性急性髓系白血病的方案。
出自爱康得生物技术